PHM Stock Analysis: Pharma Mar S.A. | MC
Biotechnology | MC, Spain | Market Cap: 1.129m EUR | 12M Return: -2.8% | ES0169501022 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 2.48M
Qual. Beats: 0
Rev. Trend: 94.7%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.9 years of data, until 10/2026
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.
Pharma Mar is a Spain-based biotechnology company focused on discovering, developing, producing, and commercializing cancer treatments. Its oncology business includes Yondelis and Zepzelca, while its pipeline includes candidates in clinical trials for cancers and other conditions.
The company also develops RNA interference medicines, which aim to reduce or silence specific gene expression. Its research draws on marine-derived compounds, and it operates across Europe, the United States, and other international markets.
- Zepzelca royalties depend on U.S. small-cell lung cancer sales growth
- Lurbinectedin Phase III results could expand treatment reach
- Yondelis sales and licensing income offset volatile R&D spending
| Net Income: 68.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.10 > 0.02 and ΔFCF/TA 5.41 > 1.0 |
| NWC/Revenue: 71.68% < 20% (prev 85.87%; Δ -14.19% < -1%) |
| CFO/TA 0.13 > 3% & CFO 52.8m > Net Income 68.4m |
| Net Debt (-103.3m) to EBITDA (53.6m): -1.93 < 3 |
| Current Ratio: 2.36 > 1.5 & < 3 |
| Outstanding Shares: last quarter (17.3m) vs 12m ago -0.55% < -2% |
| Gross Margin: 90.69% > 18% (prev 93.41%; Δ -2.72% > 0.5%) |
| Asset Turnover: 63.30% > 50% (prev 52.47%; Δ 10.83% > 0%) |
| Interest Coverage Ratio: 18.41 > 6 (EBIT TTM 45.3m / Interest Expense TTM 2.46m) |
| A: 0.42 (Total Current Assets 295.6m - Total Current Liabilities 125.4m) / Total Assets 408.4m |
| B: 0.61 (Retained Earnings 248.0m / Total Assets 408.4m) |
| C: 0.12 (EBIT TTM 45.3m / Avg Total Assets 375.0m) |
| D: 1.38 (Book Value of Equity 237.0m / Total Liabilities 171.4m) |
| Altman-Z'' = 6.98 = AAA |
| DSRI: 1.16 (Receivables 64.1m/41.8m, Revenue 237.4m/179.3m) |
| GMI: 1.03 (GM 93.41% / 90.69%) |
| AQI: 1.06 (AQ_t 0.13 / AQ_t-1 0.12) |
| SGI: 1.32 (Revenue 237.4m / 179.3m) |
| TATA: 0.04 (NI 68.4m - CFO 52.8m) / TA 408.4m) |
| Beneish M = -2.60 (Cap -4..+1) = A |
As of November 12, 2026, the stock is trading at EUR 69.30 with a total of 26,260 shares traded. Over the past week, the price has changed by +3.66%, over one month by +1.54%, over three months by -15.33% and over the past year by -2.84%.
Current recommended Stop Loss: 66.40 (which is 4.2% or 1.3 ATR below the current price).
Pharma Mar S.A. has no consensus analysts rating.
P/E Trailing = 17.628
P/E Forward = 54.0541
P/S = 4.756
P/B = 4.7966
P/EG = 0.3119
Revenue TTM = 237.4m EUR
EBIT TTM = 45.3m EUR
EBITDA TTM = 53.6m EUR
Long Term Debt = 34.6m EUR (from longTermDebt, last quarter)
Short Term Debt = 33.8m EUR (from shortTermDebt, last quarter)
Debt = 73.0m EUR (from shortLongTermDebtTotal, last quarter) + Leases 2.93m
Net Debt = -103.3m EUR (calculated: Debt 73.0m - CCE 176.3m)
Enterprise Value = 1.03b EUR (1.13b + Debt 73.0m - CCE 176.3m)
Interest Coverage Ratio = 18.41 (Ebit TTM 45.3m / Interest Expense TTM 2.46m)
EV/FCF = 24.72x (Enterprise Value 1.03b / FCF TTM 41.5m)
FCF Yield = 4.05% (FCF TTM 41.5m / Enterprise Value 1.03b)
FCF Margin = 17.48% (FCF TTM 41.5m / Revenue TTM 237.4m)
Net Margin = 28.80% (Net Income TTM 68.4m / Revenue TTM 237.4m)
Gross Margin = 90.69% ((Revenue TTM 237.4m - Cost of Revenue TTM 22.1m) / Revenue TTM)
Gross Margin QoQ = 89.35% (prev 86.21%)
Tobins Q-Ratio = 2.51 (Enterprise Value 1.03b / Total Assets 408.4m)
Interest Expense / Debt = 3.37% (Interest Expense 2.46m / Debt 73.0m)
Taxrate = 25.0% (non-US conservative default 25%)
NOPAT = 33.9m (EBIT 45.3m * (1 - 25.00%))
Current Ratio = 2.36 (Total Current Assets 295.6m / Total Current Liabilities 125.4m)
Debt / Equity = 0.31 (Debt 73.0m / totalStockholderEquity, last quarter 237.0m)
Debt / EBITDA = -1.93 (Net Debt -103.3m / EBITDA 53.6m)
Debt / FCF = -2.49 (Net Debt -103.3m / FCF TTM 41.5m)
Total Stockholder Equity = 247.3m (last 4 quarters mean from totalStockholderEquity)
RoA = 18.23% (Net Income 68.4m / Total Assets 408.4m)
RoE = 27.64% (Net Income TTM 68.4m / Total Stockholder Equity 247.3m)
RoCE = 16.06% (EBIT 45.3m / Capital Employed (Equity 247.3m + L.T.Debt 34.6m))
RoIC = 11.13% (NOPAT 33.9m / Invested Capital 305.0m)
WACC = 5.92% (E(1.13b)/V(1.20b) * Re(6.14%) + D(73.0m)/V(1.20b) * Rd(3.37%) * (1-Tc(0.25)))
Discount Rate = 6.14% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -76.81 | Cagr: -0.77%
[DCF] Terminal Value 77.97% ; FCFF base≈31.4m ; Y1≈36.0m ; Y5≈53.0m
[DCF] Fair Price = 52.14 (EV 796.8m - Net Debt -103.3m = Equity 900.1m / Shares 17.3m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.59 | # QB: 0
Revenue Correlation: 94.74 | Revenue CAGR: 16.91% | SUE: 0.74 | # QB: 0
EPS current Quarter (2027-03-31): EPS=-0.10 | Chg30d=+0.00% | Revisions=+0% | Analysts=1
EPS current Year (2026-12-31): EPS=2.39 | Chg30d=+27.98% | Revisions=-25% | GrowthEPS=-44.3% | GrowthRev=+3.9%
EPS next Year (2027-12-31): EPS=4.93 | Chg30d=-24.80% | Revisions=-25% | GrowthEPS=+106.0% | GrowthRev=+31.4%
[Analyst] Revisions Ratio: -40% (up=0, down=2)